Meeting
2021 ASCO Annual Meeting
Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
Authors
Eddy Shih-Hsin Yang
University of Alabama at Birmingham, Birmingham, AL
Eddy Shih-Hsin Yang , Benjamin Leiby , Guru P. Sonpavde , David Johnson Einstein , Zachary L. Quinn , Russell Zelig Szmulewitz , A. Oliver Sartor , William Kevin Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03076203
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5036)
DOI
10.1200/JCO.2021.39.15_suppl.5036
Abstract #
5036
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).
First Author: William Kevin Kelly
Poster
2020 Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.
First Author: Di Maria Jiang
Poster
2016 Genitourinary Cancers Symposium
Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Ulka N. Vaishampayan
Poster
2014 Genitourinary Cancers Symposium
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
First Author: Bobby Chi-Hung Liaw